Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.

Richard Zordani, Jr. Biography and Net Worth

Director of Galectin Therapeutics

Richard A. Zordani is a seasoned financial executive with extensive public accounting and Family Office experience. He has been the Director of Shareholder Services at Uline, Inc. (a distributor of shipping, packaging and industrial supplies) since 2013. Prior to joining Uline, Mr. Zordani served as a Director and Vice President for Diversified Financial Management Corp. (Pritzker family office) where he advised on complex legal and tax structures for domestic and foreign entities and trusts from 2003 through 2013 and an Audit Manager for Altschuler, Melvoin & Glasser LLP (now RSM McGladrey) from 1996 through 2003. Mr. Zordani received his undergraduate degree from the University of Illinois at Urbana/Champaign and is a Registered CPA in the state of Illinois.

How do I contact Richard A. Zordani, Jr.?: The corporate mailing address for Mr. Zordani, Jr. and other Galectin Therapeutics executives is 4960 PEACHTREE INDUSTRIAL BLVD. SUITE 240, NORCROSS GA, 30071. Galectin Therapeutics can also be reached via phone at (678) 620-3186 and via email at [email protected]. Learn More on Richard A. Zordani, Jr.'s contact information.
Has Richard A. Zordani, Jr. been buying or selling shares of Galectin Therapeutics?: Richard A. Zordani, Jr. has not been actively trading shares of Galectin Therapeutics in the last ninety days. Learn More on Richard A. Zordani, Jr.'s trading history.
Who are Galectin Therapeutics' active insiders?: Galectin Therapeutics' insider roster includes Kevin Freeman (Director), Elissa Schwartz (Director), and Richard Zordani, Jr. (Director). Learn More on Galectin Therapeutics' active insiders.
Are insiders buying or selling shares of Galectin Therapeutics?: During the last twelve months, Galectin Therapeutics insiders bought shares 7 times. They purchased a total of 12,259 shares worth more than $34,100.70. During the last twelve months, insiders at the sold shares 1 times. They sold a total of 21,323 shares worth more than $65,248.38. The most recent insider tranaction occured on October, 23rd when Director Kary Eldred bought 500 shares worth more than $1,300.00. Insiders at Galectin Therapeutics own 52.7% of the company. Learn More about insider trades at Galectin Therapeutics.
Information on this page was last updated on 10/23/2024.

Richard A. Zordani, Jr. Insider Trading History at Galectin Therapeutics

Richard A. Zordani, Jr. Buying and Selling Activity at Galectin Therapeutics

Galectin Therapeutics Company Overview

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Today's Range

Now: $2.84

$2.76

$2.90

50 Day Range

MA: $2.69

$2.47

$3.00

2 Week Range

Now: $2.84

$1.55

$4.27

Volume

53,640 shs

Average Volume

145,387 shs

Market Capitalization

$178.24 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.62

Trump won. Buy this coin now.

From Weiss Ratings | Ad